How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risk: The Context of Bisphosphonate Use

The legacy of general health and science communication has long emphasized the importance of understanding how therapeutic interventions interact with human physiology. Within this broad context, the transition from discussing medication benefits to examining potential adverse outcomes represents a natural evolution in public health discourse. As scientific literacy has expanded, so too has the recognition that even well-established treatments may carry unintended consequences under specific conditions. This foundational perspective now directs attention toward a particular area of concern: the relationship between prolonged pharmaceutical exposure and localized tissue responses. In occupational and clinical settings, the focus shifts from general health maintenance to the systematic evaluation of risk factors associated with sustained drug administration. The concept of exposure duration, dosage accumulation, and individual susceptibility becomes paramount when considering how certain medications may influence biological processes over time. The pivot from general health information to occupational exposure concern is marked by a heightened awareness of how therapeutic agents can affect specific anatomical sites. This transition requires a careful examination of the pathways through which pharmaceutical compounds interact with bone metabolism and vascular supply, particularly in the context of long-term use. The discussion now moves toward understanding the conditions under which such interactions may lead to clinically significant outcomes, without delving into specific mechanistic claims.

Bridging to Fosamax: Pharmacology and the Jawbone Connection

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). Understanding the pathophysiology of how Fosamax triggers ONJ requires examining the drug's pharmacology, the unique biology of the jawbone, and the clinical context in which the condition arises. Fosamax belongs to the class of bisphosphonates, which work by inhibiting bone resorption. This mechanism is central to its therapeutic effect in osteoporosis, where it increases bone mass and reduces the incidence of fractures, including those of the hip and spine (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, this same inhibition of osteoclast activity can disrupt normal bone turnover, particularly in the jawbone. The jawbone has a high rate of remodeling due to constant mechanical stress from chewing and the presence of teeth. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that bisphosphonate treatment, including alendronate (the active ingredient in Fosamax), can alter the mechanical stability of teeth in the alveolar socket and change tissue mineral density distribution and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes may predispose the jawbone to injury and impaired healing.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology of ONJ is thought to involve a combination of factors. Bisphosphonates accumulate in bone, particularly at sites of high turnover, and suppress osteoclast-mediated bone resorption. This suppression can lead to a reduction in the ability of the jawbone to repair microdamage and respond to infection or trauma. Osteonecrosis of the jaw, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is characterized by exposed necrotic bone in the maxillofacial region that persists for more than eight weeks. The timeline between exposure and documented harm can vary. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability suggests that individual patient factors, such as dental health and concurrent medications, play a significant role. Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Clinical Evidence

Regarding causation-related considerations for affected patients, the relationship between Fosamax use and ONJ is supported by clinical reports and biological plausibility. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These observations support a causal role for bisphosphonates in ONJ, though the condition can also occur spontaneously. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, detailing the association, risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects an awareness of the potential for long-term adverse effects.

Summary and Clinical Implications

In summary, the pathophysiology of Fosamax-induced ONJ involves bisphosphonate-mediated suppression of bone turnover in the jawbone, leading to impaired healing and necrosis, particularly when triggered by dental procedures or infection. The risk is influenced by duration of exposure and patient-specific factors. Warnings in the prescribing information address these risks, and clinical management includes consideration of drug discontinuation before invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, which can disrupt normal bone turnover in the jawbone. The jawbone has a high remodeling rate, and bisphosphonate accumulation suppresses repair of microdamage, predisposing it to necrosis, especially after dental procedures or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for Fosamax to cause ONJ symptoms?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.